关注
Ibrahim Halil Sahin MD
Ibrahim Halil Sahin MD
Assistant Professor, UPMC Hillman Cancer Center
在 upmc.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations
ZI Hu, J Shia, ZK Stadler, AM Varghese, M Capanu, E Salo-Mullen, ...
Clinical Cancer Research 24 (6), 1326-1336, 2018
3592018
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu
British journal of cancer 121 (10), 809-818, 2019
2882019
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer
I Tekedereli, SN Alpay, CDJ Tavares, ZE Cobanoglu, TS Kaoud, I Sahin, ...
PloS one 7 (7), e41171, 2012
1422012
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
IH Sahin, G Askan, ZI Hu, EM O’Reilly
Annals of Oncology 28 (12), 2950-2961, 2017
1152017
Pancreatic cancer microenvironment: a current dilemma
B Uzunparmak, IH Sahin
Clinical and translational medicine 8 (1), 2, 2019
942019
Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature
IH Sahin, SMA Kazmi, JT Yorio, NA Bhadkamkar, BK Kee, CR Garrett
Journal of Cancer 4 (4), 320, 2013
872013
Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
AO Kaseb, M Shama, IH Sahin, A Nooka, HM Hassabo, JN Vauthey, ...
Oncology 85 (4), 197-203, 2013
862013
Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science
IH Sahin, MM Hassan, CR Garrett
Cancer letters 345 (2), 249-257, 2014
802014
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches
IH Sahin, MA Lowery, ZK Stadler, E Salo-Mullen, CA Iacobuzio-Donahue, ...
Expert review of gastroenterology & hepatology 10 (8), 893-905, 2016
612016
Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior
IH Sahin, H Elias, JF Chou, M Capanu, EM O’Reilly
BMC cancer 18, 1-8, 2018
532018
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy
IH Sahin, CA Iacobuzio-Donahue, EM O’Reilly
Expert opinion on therapeutic targets 20 (3), 341-359, 2016
512016
Precision medicine for metastatic colorectal cancer: an evolving era
I Guler, G Askan, J Klostergaard, IH Sahin
Expert review of gastroenterology & hepatology 13 (10), 919-931, 2019
452019
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
RD Kim, BP Kovari, M Martinez, H Xie, IH Sahin, R Mehta, J Strosberg, ...
European Journal of Cancer 169, 93-102, 2022
432022
Association of diabetes and perineural invasion in pancreatic cancer
IH Sahin, MA Shama, M Tanaka, JL Abbruzzese, SA Curley, M Hassan, ...
Cancer medicine 1 (3), 357-362, 2012
432012
Immune‐related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration‐approved indications for …
S Das, KK Ciombor, S Haraldsdottir, Y Pumpalova, IH Sahin, G Pineda, ...
The oncologist 25 (8), 669-679, 2020
342020
Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
G Askan, IH Sahin, JF Chou, A Yavas, M Capanu, CA Iacobuzio-Donahue, ...
BMC cancer 21, 1-11, 2021
332021
Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues
IH Sahin, KK Ciombor, LA Diaz, J Yu, R Kim
American Society of Clinical Oncology Educational Book 42, 242-253, 2022
292022
Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer
IH Sahin, S Goyal, Y Pumpalova, MB Sonbol, S Das, S Haraldsdottir, ...
The Oncologist 26 (8), 668-675, 2021
292021
BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues
IH Sahin, J Klostergaard
JCO Oncology Practice 17 (12), 723-730, 2021
262021
CD44 as a drug delivery target in human cancers: where are we now?
IH Sahin, J Klostergaard
Expert Opinion on Therapeutic Targets 19 (12), 1587-1591, 2015
252015
系统目前无法执行此操作,请稍后再试。
文章 1–20